Jason Fullmer
Pediatric Pulmonology · Austin, TXNPI 1184796401
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,805 of the $74,039 with a category attached, or 70.0%. Gilead accounts for 62.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $47,149 and has fallen 100.0% since, to $20 in 2025. Among pediatric pulmonology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $454.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$46K
- Vertex$27K
- AstraZeneca$220
- Insmed, Inc.$153
- Philips North America LLC$118
- GSK$78
- plus $319 from 9 others
Across 20 payments — averaging $19,511 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$390K
What the payments were for
- Consulting fees$3,3204%
- Speaking & faculty fees$51,80570%
- Travel & lodging$16,07422%
- Food & beverage$2,8404%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 66 | $46,214 |
| Vertex | 59 | $26,938 |
| AstraZeneca | 12 | $220 |
| Insmed, Inc. | 3 | $153 |
| Philips North America LLC | 4 | $118 |
| GSK | 4 | $78 |
| Regeneron Healthcare Solutions, Inc. | 2 | $71 |
| Baxter Healthcare | 1 | $54 |
| PTC Therapeutics, Inc. | 2 | $41 |
| Chiesi USA, Inc. | 2 | $33 |
| Novartis | 2 | $30 |
| AbbVie | 2 | $28 |
| Electromed, Inc. | 2 | $23 |
| Sanofi | 1 | $22 |
| Biogen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$74,039 in reported general payments places this provider in the 95th percentile of 104 pediatric pulmonology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 97 | $2,600,522 |
| KalydecoIvacaftor | 11 | $277,698 |
| ZenpepLipase/Protease/Amylase | 19 | $174,089 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $1,247 |
| Omeprazole | 15 | $294 |
| Azithromycin | 22 | $273 |
| Montelukast Sodium | 13 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta, Kalydeco | $26,938 | $2,878,219108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 pediatric pulmonology providers in Texas.
Other pediatric pulmonology in Austin
- Joseph TayarAustin$726
- Jordan ScaloAustin$590
- June-Ku KangAustin$579
- Sarat SusarlaHouston$194K
- Kelly SmithSan Antonio$69K
- Carolyn CannonDallas$55K
- Shailendra DasFort Worth$23K
- Donna Willey-CourandSan Antonio$19K
- Fadel RuizHouston$17K
- Peter HiattHouston$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.